Esco Group is a Singapore-based life science company with a diversified portfolio and sales in over 100 countries. As a leading manufacturer of laboratory and biopharma equipment, as well as IVF medical devices, Esco offers tailored solutions that fit the needs of laboratories. Esco Group provides equipment and services to support cutting-edge research as well as commercial manufacturing of biopharmaceuticals in the Life Sciences, Medical and Healthcare divisions.
In an exclusive interview with Esco, Biotech Connection Singapore spoke to Mr. Xiangliang Lin (XL Lin), Founder & CEO of Esco Aster, an independent Contract Development and Manufacturing Organization (CDMO) in the Esco Group of companies.What is the mission which drives Esco and its spin-offs?
XL Lin: Regardless of what we do, the intrinsic mission of Esco is to invent, discover and commercialize enabling technologies to make human lives healthier and safer. For example, our biological safety cabinets (BSCs) and…
On Jan 27 2016, local biotech company InvitroCue made its debut on the Australian Securities Exchange (ASX: IVQ) - just four years after its founding. The company, a spin-off from A*STAR, just announced that it had raised an AUD 3.15 Million (SGD3.17 Million) on the ASX through a reverse takeover.
In an exclusive one-on-one interview with Biotech Connection Singapore (BCS), the InvitroCue team (co-founders Dr Steven Fang, Prof Hanry Yu, and two of the first pioneering members, Dr. Abhishek Ananthanarayanan and Dr. Shuoyu Xu) shared their experience and appeal as a success formula for entrepreneurs in the local startup scene.
BCS: Can you share with us what are the critical drivers underlying InvitroCue's success?
InvitroCue: We focus on four components essential to every company's success – technology, market strategy, business model and leaders.
Technology: We focus on two core technology developments – cell-based assay model and digital pathology. The beauty of our…